The latest price target for Humana (NYSE:HUM) was reported by Barclays on January 22, 2025. The analyst firm set a price target for $255.00 expecting HUM to fall to within 12 months (a possible -13.04% downside). 55 analyst firms have reported ratings in the last year.

The latest analyst rating for Humana (NYSE:HUM) was provided by Barclays, and Humana maintained their equal-weight rating.

The last upgrade for Humana Inc happened on November 6, 2024 when B of A Securities raised their price target to $308. B of A Securities previously had an underperform for Humana Inc.

The last downgrade for Humana Inc happened on October 7, 2024 when TD Cowen changed their price target from $402 to $261 for Humana Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humana, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humana was filed on January 22, 2025 so you should expect the next rating to be made available sometime around January 22, 2026.

While ratings are subjective and will change, the latest Humana (HUM) rating was a maintained with a price target of $253.00 to $255.00. The current price Humana (HUM) is trading at is $293.23, which is out of the analyst’s predicted range.